ストックスクリーナーアプリを入手
3.371
5.61%
0.181
前日終値:
$3.19
開ける：
$3.22
24時間の取引高:
431.97K
Relative Volume:
0.68
時価総額：
$78.09M
収益：
$317.00K
当期純損益:
$-53.47M
株価収益率:
-1.7836
EPS:
-1.89
ネットキャッシュフロー:
$-49.31M
1週間 パフォーマンス:
+31.60%
1か月 パフォーマンス:
+105.42%
6か月 パフォーマンス:
+44.59%
1年 パフォーマンス:
+135.59%
1日の値動き範囲:
$3.14
$3.3888
1週間の範囲:
$2.29
$3.3888
52週間の値動き範囲:
$1.00
$3.83
Immuneering Corp Stock (IMRX) Company Profile
名前
Immuneering Corp
セクター
電話
617-500-8080
住所
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
IMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
3.3766 | 78.09M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.77 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.50 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.63 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.29 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.24 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-15 | 繰り返されました | Needham | Buy |
| 2024-03-15 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 開始されました | Needham | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-04-19 | アップグレード | Mizuho | Neutral → Buy |
| 2023-04-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 開始されました | Mizuho | Neutral |
| 2023-02-03 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 開始されました | Chardan Capital Markets | Buy |
| 2022-04-01 | 開始されました | Oppenheimer | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Immuneering Corp (IMRX) 最新ニュース
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Asianet Newsable
Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks
Immuneering stock rises after positive pancreatic cancer trial data - Investing.com
Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus
Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan
Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada
Immuneering Corp holds annual stockholder meeting - Investing.com Australia
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.
Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus
Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan
‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus
21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus
Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX Stock News - GuruFocus
Immuneering Corp SEC 10-Q Report - TradingView
Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan
IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan
Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com
What technical indicators reveal about IMRX stock - uspostnews.com
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World
Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan
Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World
Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC - The AM Reporter
Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World
Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks
Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan
Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks
Immuneering Corp SEC 10-K Report - TradingView
Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com
Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan
Immuneering appoints Igor Matushansky as CMO - The Pharma Letter
Immuneering appoints new Chief Medical Officer - Investing.com
Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan
Immuneering Corp (IMRX) 財務データ
収益
当期純利益
現金流量
EPS
Immuneering Corp (IMRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schall Thomas J. | Director |
Jun 17 '25 |
Buy |
2.21 |
40,485 |
89,278 |
43,385 |
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):